The Women's Oncology Review, Volume 6, Issue 1-2 (2007)

Browse this journal

The Women's Oncology Review, Volume 6, Issue 1-2 (2007)

See all volumes and issues
Volume 6, 2006-2007 Vol 5, 2005 Vol 4, 2004
Download citations Download PDFs Download issue

Editorial Article

Editorial
Biochemical recurrent ovarian cancer: CA 125 elevation without symptoms or clinical evidence of disease. What is the optimal management?
Emily Berry & Jean A. Hurteau
Pages: 1-5
Published online: 04 Dec 2011
First Page PreviewforBiochemical recurrent ovarian cancer: CA 125 elevation without symptoms or clinical evidence of disease. What is the optimal management? | References | PDF (407.5 KB)
  • 7 Views
  • 0 CrossRef citations
  • 0Altmetric

Review Article

Review Article
The use of cytoprotectants in the treatment of gynecological malignancies
David H. Wei, Leester Wu, Peter B. Schiff & Thomas J. Herzog
Pages: 7-14
Published online: 04 Dec 2011
First Page PreviewforThe use of cytoprotectants in the treatment of gynecological malignancies | References | PDF (144.5 KB)
  • 9 Views
  • 0 CrossRef citations
  • 0Altmetric
Review Article
Current controversies in the biology and management of ovarian tumors of low malignant potential
William E. Winter, Douglas N. Brown & Charles A. Leath
Pages: 15-25
Published online: 04 Dec 2011
AbstractforCurrent controversies in the biology and management of ovarian tumors of low malignant potential | References | PDF (188.3 KB)
  • 2 Views
  • 0 CrossRef citations
  • 0Altmetric
Review Article
Neoadjuvant chemotherapy for ovarian cancer: pro versus con
Eric L. Eisenhauer, Robert E. Bristow & Dennis S. Chi
Pages: 27-35
Published online: 04 Dec 2011
AbstractforNeoadjuvant chemotherapy for ovarian cancer: pro versus con | References | PDF (162 KB)
  • 3 Views
  • 0 CrossRef citations
  • 0Altmetric
Review Article
Management of the axilla
G. Querci della Rovere & John R. Benson
Pages: 37-45
Published online: 04 Dec 2011
AbstractforManagement of the axilla | References | PDF (166 KB)
  • 2 Views
  • 0 CrossRef citations
  • 0Altmetric
Review Article
HER 1/2 inhibitors in breast cancer: Uses in adjuvant and metastatic therapy
Todd J. Alekshun & Pamela N. Munster
Pages: 47-54
Published online: 04 Dec 2011
First Page PreviewforHER 1/2 inhibitors in breast cancer: Uses in adjuvant and metastatic therapy | References | PDF (151 KB)
  • 4 Views
  • 0 CrossRef citations
  • 0Altmetric

Commentary

Article Commentary
Cyclin D1 antagonizes BRCA1 repression of estrogen receptor α activity
Wang C, Fan S, Li Z, Fu M, Rao M, Ma Y, Lisanti MP, Albanese C, Katzenellenbogen BS, Kushner PJ, Weber B, Rosen EM, Pestell RG. Cancer Res 2005;65:6557–6567
Paraskevi Vogiatzi
Pages: 55-57
Published online: 04 Dec 2011
First Page PreviewforCyclin D1 antagonizes BRCA1 repression of estrogen receptor α activity | References | PDF (72.3 KB)
  • 2 Views
  • 0 CrossRef citations
  • 0Altmetric
Article Commentary
Protein chip discovery of secreted proteins regulated by the phosphatidylinositol 3-kinase pathway in ovarian cancer cell lines
M. Moscova, D.J. Marsh, R.C. Baxter. Cancer Res 2006;66:1376–1383
Paraskevi Vogiatzi & Francesca Sanseverino
Pages: 59-61
Published online: 04 Dec 2011
First Page PreviewforProtein chip discovery of secreted proteins regulated by the phosphatidylinositol 3-kinase pathway in ovarian cancer cell lines | References | PDF (72.2 KB)
  • 1 Views
  • 0 CrossRef citations
  • 0Altmetric
Article Commentary
Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance
F.W. Wamunyokoli, T. Bonome, J.Y. Lee, C.M. Feltmate, W.R. Welch, M. Radonovich, C. Pise-Masison, J. Brady, K. Hao, R.S. Berkowitz, S. Mok, M.J. Birrer. Clin Cancer Res 2006;12:690–700
Marco Cassone
Pages: 63-66
Published online: 04 Dec 2011
First Page PreviewforExpression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance | References | PDF (84.4 KB)
  • 0 Views
  • 0 CrossRef citations
  • 0Altmetric
Article Commentary
Radiation after breast conservative surgery or after mastectomy reduces local recurrence and improves overall survival in breast cancer
Early Breast Cancer Trailists' Collaborative Group. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005;366:2087–2106
Thomas A. Buchholz
Pages: 67-69
Published online: 04 Dec 2011
First Page PreviewforRadiation after breast conservative surgery or after mastectomy reduces local recurrence and improves overall survival in breast cancer | References | PDF (66.6 KB)
  • 0 Views
  • 1 CrossRef citations
  • 0Altmetric

Original Article

Article
B7-H4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer
Simon I, Zhou S, Corral L, et al. B7-H4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res 2006;66(3):1570–1575.
Alessandra Rossi
Pages: 71-73
Published online: 04 Dec 2011
First Page PreviewforB7-H4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer | References | PDF (69.6 KB)
  • 3 Views
  • 0 CrossRef citations
  • 0Altmetric

Commentary

Article Commentary
Long term toxicity following interstitial breast brachytherapy: results from RTOG 95-17
Kuske PR, Winter K, Arthur DW, et al. Phase II trial of brachytherapy alone after lumpectomy for select breast cancer: toxicity analysis of RTOG 9517. Int J Radiat Oncol Biol Phys 2006;65(1):45–51.
David E. Wazer & Seth A. Kaufman
Pages: 75-77
Published online: 04 Dec 2011
First Page PreviewforLong term toxicity following interstitial breast brachytherapy: results from RTOG 95-17 | References | PDF (68.6 KB)
  • 2 Views
  • 0 CrossRef citations
  • 0Altmetric
Article Commentary
Post-mastectomy radiation for breast cancer patients with small tumors and one to three positive lymph nodes
Troung PT, Olivotto IA, Kader HA, Panades M, Speers CH, Berthelet E. Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary lymph nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy. Int J Rad Oncol Biol Phys 2006;61:1337–47.
Wendy A. Woodward
Pages: 79-80
Published online: 04 Dec 2011
CitationforPost-mastectomy radiation for breast cancer patients with small tumors and one to three positive lymph nodes | References | PDF (54.1 KB)
  • 0 Views
  • 0 CrossRef citations
  • 0Altmetric
Article Commentary
Should post-mastectomy radiation be used for node-negative breast cancer patients?
Troung PT, Lesperance M, Culhaci A, Kader HA, Speers CH, Olivotto IA. Patient subsets with T1-T2, node-negative breast cancer at high locoregional recurrence risk after mastectomy. Int J Rad Oncol Biol Phys 2005;62:175–182
Wendy A. Woodward
Pages: 81-82
Published online: 04 Dec 2011
CitationforShould post-mastectomy radiation be used for node-negative breast cancer patients? | References | PDF (51.8 KB)
  • 0 Views
  • 0 CrossRef citations
  • 0Altmetric
Article Commentary
DCIS of the breast: Solving the puzzle
J.S. Wong, C.M. Kaelin, S.L. Troyan, M.A. Gadd, R. Gelman, S.C. Lester, S.J. Schnitt, D.C. Sgroi, B.J. Silver, J.R. Harris and B.L. Smith. J Clin Oncol 2006;24:1031–1036
Upendra Parvathaneni & Thomas A. Buchholz
Pages: 83-84
Published online: 04 Dec 2011
CitationforDCIS of the breast: Solving the puzzle | References | PDF (56.9 KB)
  • 0 Views
  • 0 CrossRef citations
  • 0Altmetric
Article Commentary
Concurrent chemo-radiotherapy in operable breast cancer
Rouesse J, et al. A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node positive breast cancer: final results. Int J Radiation Oncology Biol Phys R 2006;64:1072–1080.
Bruce G. Haffty
Pages: 85-87
Published online: 04 Dec 2011
First Page PreviewforConcurrent chemo-radiotherapy in operable breast cancer | References | PDF (73.8 KB)
  • 7 Views
  • 0 CrossRef citations
  • 0Altmetric
Article Commentary
Is concurrent radiation and paclitaxel in breast cancer patients safe?
H.R. Burstein, J.R. Bellon, et al. Int J Rad Oncol Biol Phys 2006;64:496–504
Tse-Kuan Yu
Pages: 89-91
Published online: 04 Dec 2011
First Page PreviewforIs concurrent radiation and paclitaxel in breast cancer patients safe? | References | PDF (68.2 KB)
  • 5 Views
  • 0 CrossRef citations
  • 0Altmetric
Article Commentary
Age-related patterns of care of breast cancer patients
S.S. Thwin, A.K. Fink, T.L. Lashan, R.A. Silliman. Cancer 2005;104:936–942
Cathie T. Chung
Pages: 93-95
Published online: 04 Dec 2011
First Page PreviewforAge-related patterns of care of breast cancer patients | References | PDF (71.4 KB)
  • 1 Views
  • 0 CrossRef citations
  • 0Altmetric
Article Commentary
Neuroprotective effects of vitamin E
A.A. Argyuriou, E. Chroni, et al. Neurology 2005;64:26–31
Daniela Matei
Pages: 97-98
Published online: 04 Dec 2011
CitationforNeuroprotective effects of vitamin E | References | PDF (55.7 KB)
  • 1 Views
  • 0 CrossRef citations
  • 0Altmetric
Article Commentary
Docetaxel more active than paclitaxel as second-line therapy for metastatic breast cancer
S.E. Jones, J. Erban, B. Overmoyer, G.T. Budd, L. Hutchins, E. Lower, L. Laufman, S. Sundaram, W.J. Urba, K.I. Pritchard, R. Mennel, D. Richards, S. Olsen, M.L. Meyers, P.M. Ravdin. J Clin Oncol 2005;23(24):5542–5551
Aileen L. Chen & Anna Pavlick
Pages: 99-100
Published online: 04 Dec 2011
CitationforDocetaxel more active than paclitaxel as second-line therapy for metastatic breast cancer | References | PDF (57.5 KB)
  • 7 Views
  • 0 CrossRef citations
  • 0Altmetric
Article Commentary
Is the HERA trial the hero we are looking for: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer?
M.J. Piccart-Gebhart, M. Procter, B. Leyland-Jones, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. NEJM 2005;353:1659–1672.
Jason M. Kaplan & Gavin Marx
Pages: 101-103
Published online: 04 Dec 2011
First Page PreviewforIs the HERA trial the hero we are looking for: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer? | References | PDF (72.1 KB)
  • 1 Views
  • 3 CrossRef citations
  • 0Altmetric
Article Commentary
High dose chemotherapy for breast cancer: Out with the old, in with the new?
U.A. Nitz, S. Mohrmann, J. Fischer, et al. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral blood stem cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. Lancet 2005;366:1935–1944.
Vinod Pullarkat & Stephen J. Forman
Pages: 105-107
Published online: 04 Dec 2011
First Page PreviewforHigh dose chemotherapy for breast cancer: Out with the old, in with the new? | References | PDF (71 KB)
  • 1 Views
  • 0 CrossRef citations
  • 0Altmetric
Article Commentary
High dose ifosfamide plus doxorubicin for advanced or metastatic gynecologic sarcomas
S. Leyvraz, M. Zweifel, G. Jundt, A. Lissoni, T. Cerny, C. Sessa, M. Fey, D. Dietrich, H.P. Honegger. Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas. Ann Oncol 2006;17:646–651.
Martee L. Hensley
Pages: 109-110
Published online: 04 Dec 2011
CitationforHigh dose ifosfamide plus doxorubicin for advanced or metastatic gynecologic sarcomas | References | PDF (58.3 KB)
  • 3 Views
  • 0 CrossRef citations
  • 0Altmetric

Original Article

Article
Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer
Mitch Dowsett, Ian E. Smith, Steve R. Ebbs, et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer_a study from the IMPACT trialists. Clin Cancer Res 2006;Feb 1;12(3 Pt 2):1024s–1030s.
Brachelente Giovanni
Pages: 111-113
Published online: 04 Dec 2011
First Page PreviewforProliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer | References | PDF (67.9 KB)
  • 3 Views
  • 0 CrossRef citations
  • 0Altmetric

Commentary

Article Commentary
MPA is more effective than venlafaxine for hot flushes
Loprinzi C.L. et al. Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flushes: North Central Cancer Treatment Group Trial N99C7. J Clin Oncol 2006;24:1409–1414.
Andreas Makris
Pages: 115-116
Published online: 04 Dec 2011
CitationforMPA is more effective than venlafaxine for hot flushes | References | PDF (53.5 KB)
  • 1 Views
  • 0 CrossRef citations
  • 0Altmetric
Article Commentary
Pseudomyxoma peritonei: A case series and review of the literature
M.L. Hopkins, A.D. Depetrillo, T. Le, M. Fung Kee Fung. Int J Gynecol Cancer 2005;15:32–36
Brigitte Miller
Pages: 117-118
Published online: 04 Dec 2011
CitationforPseudomyxoma peritonei: A case series and review of the literature | References | PDF (52.4 KB)
  • 0 Views
  • 0 CrossRef citations
  • 0Altmetric

Explore articles

Explore the most recently published articles

Pseudomyxoma peritonei: A case series and review of the literature
Brigitte Miller
Article Commentary | Published online: 4 Dec 2011
Cyclin D1 antagonizes BRCA1 repression of estrogen receptor α activity
Paraskevi Vogiatzi
Article Commentary | Published online: 4 Dec 2011
The use of cytoprotectants in the treatment of gynecological malignancies
David H. Wei et al.
Review Article | Published online: 4 Dec 2011
Post-mastectomy radiation for breast cancer patients with small tumors and one to three positive lymph nodes
Wendy A. Woodward
Article Commentary | Published online: 4 Dec 2011